Evidence map›Paper›PMID 36837502›Full record

ArticleMedicina (Kaunas, Lithuania)2023

ACE2-Inhibitory Effects of Bromelain and Ficin in Colon Cancer Cells.

Babak Pakbin, Shaghayegh Pishkhan Dibazar, Samaneh Allahyari, Hanifeh Shariatifar, Wolfram Manuel Brück, Alireza Farasat

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Babak PakbinWerner Siemens Chair of Synthetic Biotechnology, Department of Chemistry, Technical University of Munich (TUM), Lichtenberg Str. 4, 85748 Garching bei München, Germany.
Shaghayegh Pishkhan DibazarCellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin 34199-15315, Iran.ORCID 0000-0002-4811-5312
Samaneh AllahyariCellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin 34199-15315, Iran.
Hanifeh ShariatifarFood and Drug Laboratory Research Center, Food and Drug Administration, MOH & ME, Tehran 1435643314, Iran.
Wolfram Manuel BrückInstitute for Life Technologies, University of Applied Sciences Western Switzerland Valais-Wallis, 1950 Sion, Switzerland.ORCID 0000-0002-4516-5146
Alireza FarasatCellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin 34199-15315, Iran.
Qazvin University of Medical Sciences · IRAcademic Center for Education, Culture and Research · IRIran Nanohealth Committee Food and Drug Organization · IRSiemens (Germany) · DE

Funding

Qazvin University of Medical Sciences 400000061
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Angiotensin-Converting Enzyme 2Colonic NeoplasmsBromelainsCaco-2 CellsFicainHumansAngiotensin-Converting Enzyme 2BromelainsFicainACE2-inhibitorybromelaincaco-2 cell lineficin

Identifiers

PMID36837502
PMCPMC9962737
OpenAlexW4319439901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.